Guidance and quality standards Awaiting development

Skip to filtersSkip to results

Skip to results

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 10 of 301

TitleType
10395 - Aprocitentan for treating resistant hypertension TS ID 10395Technology appraisal guidance
Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095Technology appraisal guidance
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer TS ID 11831Technology appraisal guidance
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]Technology appraisal guidance
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma TS ID 11954Technology appraisal guidance
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]Technology appraisal guidance
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia TS ID 11768Technology appraisal guidance
Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma TS ID 11823Technology appraisal guidance
Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy TS ID 11904Technology appraisal guidance
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6339]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All